Financings Routine −

NurExone Announces Closing of Non-Brokered Private Placement

Dilutive financing at a discount underscores cash burn concerns in pre-revenue exosome developer

By The Northwire Desk — AI Analysis Jun 30, 2026 · 08:31 NRX · 0.57 NurExone Biologic Inc.

Executive Summary

NurExone Biologic Inc. closed a non-brokered private placement of 1,012,573 units.
Pricing was set at C$0.62 per unit, generating gross proceeds of approximately C$627,795.26 (roughly $460,000 USD).
Proceeds are designated for general working capital purposes.
Each unit consists of one common share and one common share purchase warrant.
Warrant terms include a C$0.78 exercise price, a 36-month term, and an acceleration clause if the TSXV VWAP reaches C$1.55 for 20 consecutive days.
No insiders participated, and no finder's fees were paid.
Closing is subject to TSXV approval and carries a statutory hold period of four months and one day.

Material Impact

The capital raise is small relative to the company's operating burn and provides only a short-term cash bridge.
The offering price of C$0.62 (~$0.45 USD) represents a ~20% discount to the recent trading range of $0.55–$0.57 USD, indicating management's need to attract capital at a depressed valuation.
The issuance dilutes existing shareholders by approximately 1.1% on a fully diluted basis (including warrants).
The transaction does not alter the company's strategic direction, clinical timeline, or commercial roadmap. It merely extends the cash runway by a few months.
Given the explicit going concern warning in the Q1 2026 MD&A, this financing is a predictable, defensive measure rather than a transformative event.

NRX · Price

Company Overview

NurExone Biologic Inc. is a pre-revenue biotechnology company focused on exosome-based therapeutics.
Lead candidate: ExoPTEN, an exosome-siRNA delivery system targeting acute spinal cord injury and optic nerve damage.
Dual-track strategy: advancing regulated therapeutic development (ExoPTEN) while commercializing naive MSC-derived exosomes for wellness and aesthetics through its U.S. subsidiary, Exo-Top Inc.
Strong intellectual property portfolio with granted patents in the U.S., Israel, Australia, and Korea.
Preclinical data has demonstrated dose-dependent vision recovery in glaucoma models and motor function restoration in spinal cord injury models.
Aiming for FDA IND submission in H2 2026 and First-in-Human trials in 2027.

More from NurExone Biologic Inc.